Skip to content

Frontlight ResearchEarly access

Institution

The Christie NHS Foundation Trust

Manchester, United KingdomWebsite

Also known as: Christie Hospital NHS Foundation Trust

241running trials
106closed trials
11,210publications (OpenAlex)

Running trials

Not yet recruiting
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· Phase 1· Eli Lilly and Company· Source
Recruiting
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source
Recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991· Phase 1· Charm Therapeutics· Source
Recruiting
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
NCT07723703· Phase 1· Amphista Therapeutics Ltd· Source
Recruiting
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
NCT07718243· Phase 1/2· Institute of Cancer Research, United Kingdom· Source
Recruiting
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
NCT07751133· Phase 3· University College, London· Source
Recruiting
Pencil Beam Scanning Proton Beam Radiotherapy for the Management of Abdominal Neuroblastoma
NCT06804447· The Christie NHS Foundation Trust· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Recruiting
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
NCT07613723· Phase 1· Zelluna Immunotherapy AS· Source
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459· Phase 2· CatalYm GmbH· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
NCT07372885· Phase 1/2· University of Manchester· Source
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778· Phase 2· CellCentric Ltd.· Source
Enrolling by invitation
DENTOFACIAL-PBT Stage 2 - Feasibility Study
NCT07057284· Manchester University NHS Foundation Trust· Source
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871· Phase 1· Janssen Research & Development, LLC· Source
Not yet recruiting
Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma
NCT07293598· The Christie NHS Foundation Trust· Source
Recruiting
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598· Phase 2· Theradex· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187· Phase 2/3· AbbVie· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488· Phase 1/2· Celgene· Source
Recruiting
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
NCT06434493· The Christie NHS Foundation Trust· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
NCT05903430· The Christie NHS Foundation Trust· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499· Phase 1· Pfizer· Source
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502· Phase 3· Celgene· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960· Phase 1/2· AbbVie· Source
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source

Showing 50 of 241.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer39 recruiting
Childhood cancers21 recruiting
Ovarian cancer20 recruiting
Prostate cancer15 recruiting
Colorectal cancer13 recruiting
Bladder cancer10 recruiting
Gastric and oesophageal cancer10 recruiting
Melanoma10 recruiting
Head and neck cancer9 recruiting
Multiple myeloma9 recruiting
Pancreatic cancer9 recruiting
Triple-negative breast cancer8 recruiting
Myelodysplastic syndromes7 recruiting
Acute myeloid leukaemia6 recruiting
Liver and biliary tract cancer6 recruiting
Metastatic breast cancer6 recruiting
Kidney cancer5 recruiting
Endometrial cancer4 recruiting
Follicular lymphoma4 recruiting
Cervical cancer3 recruiting
Chronic lymphocytic leukaemia3 recruiting
Chronic myeloid leukaemia3 recruiting
Thyroid cancer3 recruiting
Acute lymphoblastic leukaemia2 recruiting
Brain metastases2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Glioblastoma2 recruiting
Sarcoma2 recruiting
Hearing loss1 recruiting
Hodgkin lymphoma1 recruiting
Mantle cell lymphoma1 recruiting
Mesothelioma1 recruiting
Neuroblastoma1 recruiting
Testicular cancer1 recruiting

Closed trials

Completed
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
NCT07295951· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001· Phase 1· Janssen Research & Development, LLC· Source
Terminated
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
NCT06523803· Phase 1· Zymeworks BC Inc.· Source
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780· Phase 1/2· Regeneron Pharmaceuticals· Source
Completed
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
NCT06322927· The Christie NHS Foundation Trust· Source
Terminated
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials
NCT06868355· University of Manchester· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Terminated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NCT05678257· Phase 2· NuCana plc· Source
Terminated
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NCT05714553· Phase 1/2· NuCana plc· Source
Terminated
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
NCT04854096· Phase 2· NS Pharma, Inc.· Source
Terminated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316· Phase 2· Agenus Inc.· Source
Completed
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585· Phase 1· C4 Therapeutics, Inc.· Source
Completed
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
NCT05441501· Phase 1· Janssen Research & Development, LLC· Source
Withdrawn
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
NCT04315246· Phase 1/2· Y-mAbs Therapeutics· Source
Completed
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933· Phase 1· Shattuck Labs, Inc.· Source
Completed
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239· Phase 3· PharmaMar· Source
Completed
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
NCT05444530· Phase 1· Janssen Research & Development, LLC· Source
Terminated
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
NCT05389462· Phase 1· ADC Therapeutics S.A.· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Gilead Sciences· Source
Completed
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
NCT05366725· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439· Phase 1· Shattuck Labs, Inc.· Source
Completed
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
NCT04960059· The Christie NHS Foundation Trust· Source
Recruiting
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789· Phase 1/2· Nuvalent Inc.· Source
Completed
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725· Phase 2· Revolution Medicines, Inc.· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04958785· Phase 2· Gilead Sciences· Source
Completed
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
NCT04907851· Phase 2· Redx Pharma Ltd· Source
Completed
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT05091346· Phase 1/2· Eisai Inc.· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Completed
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
NCT04811027· Phase 2· Immutep S.A.S.· Source
Completed
Lung Screening in People Cured of Hodgkin Lymphoma
NCT04986189· The Christie NHS Foundation Trust· Source
Terminated
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Gilead Sciences· Source
Completed
Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers
NCT04750109· The Christie NHS Foundation Trust· Source
Terminated
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source
Completed
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
NCT04526899· Phase 2· BioNTech SE· Source
Completed
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
NCT04833114· Phase 3· GWT-TUD GmbH· Source
Completed
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
NCT04499924· Phase 2/3· Seagen Inc.· Source
Completed
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
NCT04742101· Phase 1/2· Institut de Recherches Internationales Servier· Source
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT04649359· Phase 2· Pfizer· Source
Completed
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04609826· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT04540796· Phase 1· Janssen Research & Development, LLC· Source
Completed
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04362072· Phase 4· Pfizer· Source
Completed
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
NCT04526106· Phase 1/2· Elevar Therapeutics· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

Showing 50 of 106.

Registry name variants (66)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

The Christie NHS Foundation Trust
Manchester, M20 4BX
242 trials
The Christie NHS Foundation Trust - Christie Hospital
Manchester, Greater Manchester M204BX
17 trials
Christie Hospital NHS Foundation Trust
Manchester, M20 4BX
8 trials
Christie NHS Foundation Trust
Manchester, M20 4BX
8 trials
The Christie Hospital NHS Foundation Trust
Manchester, M20 4BX
5 trials
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, M20 4BX
4 trials
The Christie NHS Foundation Trust
Withington, Greater Manchester M20 1BX
3 trials
- NCT07096778Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  Contact: CCS1477-04 Clinical Operations
- NCT07202260Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
- NCT04778397Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
The Christie NHS Foundation Trust - Medical Oncology
Manchester, M20 4BX
3 trials
- NCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
  Contact: Zoe Brammer
- NCT04907851A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
- NCT04987203Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
The Christie Nhs Foundation Trust
Manchester Greater, M204BX
2 trials
- NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- NCT07023627A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
The Christie NHS Foundation Trust, Department of Medical Oncology
Manchester, M20 4BX
2 trials
- NCT05502237Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  Contact: Novartis Pharmaceuticals
The Christie NHS Foundation Trust - PPDS
Manchester, M20 4GJ
2 trials
- NCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- NCT01909453Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Cancer Research UK - Christie Hospital Foundation NHS Trust - Dept of Medical Oncology
Manchester, M20 4BX
1 trial
- NCT04083235A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Christie NHS Foundation Trust
GB Manchester, M20 4BX
1 trial
- NCT05091567A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Christie NHS Foundation Trust (Site 0275)
Manchester, M20 4BX
1 trial
- NCT03829319Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
Christie NHS Foundation Trust (Site 0604)
Manchester, M20 4GJ
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Christie NHS Foundation Trust (Site 0805)
Manchester, M20 4BX
1 trial
- NCT03797326Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Christie NHS Foundation Trust (Site 1409)
Manchester, M20 4BX
1 trial
- NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Christie NHS Foundation Trust (Site 2903)
Manchester, M20 4BX
1 trial
- NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Department of Medical Oncology, The Christie NHS Foundation Trust
Manchester, M20 4BX
1 trial
- NCT02684006A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
The Christie Hospital NHS Foundation Trust (Site 1503)
Manchester, M20 4BX
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The Christie Hospital NHS Foundation Trust (Site 2243)
Manchester, M20 4BX
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
The Christie Nhs Foundation Foundation Trust
Manchester, M20 4BX
1 trial
- NCT06162572Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
The Christie NHS Foundation Trust
Lancaster
1 trial
- NCT06486883Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
  Contact: MEDSIR
The Christie NHS Foundation Trust
Wythenshawe, M23 9LT
1 trial
- NCT03134118Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
The Christie NHS Foundation Trust - 2802
Manchester, London M20 4BX
1 trial
- NCT05671510ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
The Christie NHS Foundation Trust - Cancer Research Centre
Manchester, M20 4BX
1 trial
- NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
  Contact: Moderna WeCare Team
The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
Manchester, M20 4BX
1 trial
- NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
The Christie NHS Foundation Trust - Christie Hospital /ID# 276276
Manchester, M20 4BX
1 trial
- NCT06953960A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
The Christie NHS Foundation Trust - Christie Hospital /ID# 277304
Manchester, M20 4BX
1 trial
- NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
The Christie NHS Foundation Trust (PTC)
Manchester, M20 4BX
1 trial
- NCT04307576A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
  Contact: Anna Castleton, M.D. (principal investigator)
The Christie NHS Foundation Trust (Site 0282)
Manchester, M20 4BX
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The Christie NHS Foundation Trust (Site 0397)
Manchester, M20 4BX
1 trial
- NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The Christie NHS Foundation Trust (Site 0405)
Manchester, M20 4BX
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 0537)
Manchester, M20 4BX
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
The Christie NHS Foundation Trust (Site 0575)
Manchester, M20 4BX
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
The Christie NHS Foundation Trust (Site 0603)
Manchester, m20 4bx
1 trial
- NCT06504394A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
The Christie NHS Foundation Trust (Site 0907)
Manchester, m20 4bx
1 trial
- NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
The Christie NHS Foundation Trust (Site 1001)
Manchester, m20 4bx
1 trial
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
The Christie NHS Foundation Trust (Site 1300)
Manchester, M20 4BX
1 trial
- NCT07519772A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 1306)
Manchester, M20 4BX
1 trial
- NCT06305767A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
The Christie NHS Foundation Trust (Site 1400)
Manchester, M20 4BX
1 trial
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
The Christie NHS Foundation Trust (Site 1401)
Manchester, M20 4BX
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The Christie NHS Foundation Trust (Site 1436)
Manchester, m20 4bx
1 trial
- NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 1602)
Manchester, M20 4BX
1 trial
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
The Christie NHS Foundation Trust (Site 1608)
Manchester, m20 4bx
1 trial
- NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 1755)
Manchester, M20 4BX
1 trial
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 1814)
Manchester, m20 4bx
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
The Christie NHS Foundation Trust (Site 1909)
Manchester, M20 4BX
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
The Christie NHS Foundation Trust (Site 2066)
Manchester, M20 4BX
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 2208)
Manchester, M20 4BX
1 trial
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 2209)
Manchester, M20 4BX
1 trial
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
The Christie NHS Foundation Trust (Site 2405)
Manchester, M20 4GJ
1 trial
- NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
The Christie NHS Foundation Trust (Site 2602)
Manchester, M20 4BX
1 trial
- NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 2604)
Manchester, m20 4bx
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The Christie NHS Foundation Trust (Site 2804)
Manchester, m20 4bx
1 trial
- NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 3301)
Manchester, M20 4BX
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The Christie NHS Foundation Trust (Site 3307)
Manchester, m20 4bx
1 trial
- NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
The Christie NHS Foundation Trust (Site 3400)
Manchester, M20 4BX
1 trial
- NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
The Christie NHS Foundation Trust (Site 3901)
Manchester, M20 4BX
1 trial
- NCT06780137A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
  Contact: Toll Free Number
The Christie NHS Foundation Trust (Site 4003)
Manchester, M20 4BX
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 5400)
Manchester, M20 4BX
1 trial
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
The Christie NHS Foundation Trust (Site 7007)
Manchester, m20 4bx
1 trial
- NCT05458297A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
The Christie NHS Foundation Trust - SSC Parent
Manchester, M20 4BX
1 trial
- NCT05306340A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
The Christie NHS Foundation trust - The Christie NHS Foundation Trust
Manchester, M20 4BX
1 trial
- NCT03818503E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
  Contact: EORTC HQ
The Christie - The Christie NHS Foundation Trust
Manchester, M20 4BX
1 trial
- NCT04526899A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
The Research And Development Office, The Christie NHS Foundation Trust
Manchester, M204BX
1 trial
- NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Conditions

Diseases this institution publishes on or runs trials for.

Lung cancer119 works · 83 trials
Prostate cancer63 works · 27 trials
Melanoma43 works · 26 trials
Ovarian cancer29 works · 34 trials
Follicular lymphoma16 works · 9 trials
Brain metastases13 works · 2 trials
Mesothelioma9 works · 3 trials
Myelodysplastic syndromes7 works · 11 trials
Testicular cancer3 works · 1 trial

Institution data: ROR 03v9efr22 (CC0-1.0)Updated 14 Nov 2026

Report an error